Brief: Diamedica Therapeutics Announces Expansion Of DM199 (Rinvecalinase Alfa) Program Into Preeclampsia
26/06/2024 13:14
June 26 (Reuters) - DiaMedica Therapeutics Inc DMAC.O :
* DIAMEDICA THERAPEUTICS ANNOUNCES EXPANSION OF DM199
(RINVECALINASE ALFA) PROGRAM INTO PREECLAMPSIA
* DIAMEDICA THERAPEUTICS: PREECLAMPSIA PROGRAM TO BE
INITIATED
WITH A PHASE 2 INVESTIGATOR-SPONSORED TRIAL BEGINNING IN Q4 2024
Source text for Eikon: ID:nBw3wBQspa
Further company coverage: DMAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program